New hope for myeloma patients: could ramantamig plus daratumumab outperform standard care?

NCT ID NCT07665450

Not yet recruiting Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This phase 3 trial will compare a new treatment, ramantamig plus daratumumab, against two standard drug combinations for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The study aims to see if the new combo can keep the cancer from progressing longer and achieve deeper remission. Around 1,000 participants will be enrolled, and the trial is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ramantamig (a drug) plus daratumumab, compared to standard combinations of daratumumab, bortezomib, lenalidomide, and dexamethasone
What this could lead to: If successful, this could offer a more effective first-line treatment option for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant, potentially delaying disease progression.
What could go wrong: This is a large phase 3 trial, but it hasn't started yet. The new drug combination may not prove better than existing treatments, and side effects from the drug combination are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.